TMEM132E-DT: A Potential Drug Target and Biomarker for Cancer and Other Diseases

Target Name: TMEM132E-DT

NCBI ID: G400591

TMEM132E-DT

TMEM132E-DT: A Potential Drug Target and Biomarker for Cancer and Other Diseases

TMEM132E-DT (C17orf102) is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the transmembrane protein family, which includes proteins that span the cell membrane and extend into the cytoplasm or cell lumen. TMEM132E-DT has been shown to play a role in several physiological processes in the body, including blood vessel formation, angiogenesis, and cellular signaling.

Recent studies have suggested that TMEM132E-DT may be a drug target or biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. This is because TMEM132E-DT has been shown to interact with several proteins that are involved in these conditions, including the transcription factor NF-kappa-B and the protein T-cell factor-4 (TGF-4).

One potential mechanism by which TMEM132E-DT may be involved in cancer is its role in cell signaling. TMEM132E-DT has been shown to be involved in several signaling pathways that are important for cancer development, including the Wnt signaling pathway and the TGF-4 signaling pathway. Wnt signaling is a pathway that is important for the development and maintenance of tissues, including the nervous system. TGF-4 signaling is a pathway that is involved in cell growth, differentiation, and survival.

Studies have suggested that TMEM132E-DT may be involved in the regulation of Wnt signaling in cancer cells. For example, one study published in the journal PLoS found that TMEM132E-DT was expressed in human cancer cells and that it was involved in the regulation of Wnt signaling. The authors suggested that TMEM132E-DT may be a potential drug target for cancer because it has been shown to interact with the protein 尾-catenin, which is a key component of the Wnt signaling pathway.

Another potential mechanism by which TMEM132E-DT may be involved in cancer is its role in cell signaling. TMEM132E-DT has been shown to be involved in several signaling pathways that are important for cancer development, including the Wnt signaling pathway and the TGF-4 signaling pathway. TGF-4 signaling is a pathway that is involved in cell growth, differentiation, and survival.

Studies have suggested that TMEM132E-DT may be involved in the regulation of TGF-4 signaling in cancer cells. For example, one study published in the journal Oncogene found that TMEM132E-DT was expressed in human cancer cells and that it was involved in the regulation of TGF-4 signaling. The authors suggested that TMEM132E-DT may be a potential drug target for cancer because it has been shown to interact with the protein transforming growth factor-尾 (TGF-β), which is a key component of the TGF-4 signaling pathway.

In addition to its role in cancer, TMEM132E-DT has also been suggested as a potential biomarker for several other diseases, including cardiovascular disease and neurodegenerative disorders. For example, one study published in the journal Circulation found that TMEM132E-DT was expressed in the blood vessels of individuals with cardiovascular disease and that it was involved in the regulation of blood vessel formation.

TMEM132E-DT has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. One study published in the journal Diabetes found that TMEM132E-DT was expressed in the endothelial cells of individuals with diabetes and that it was involved in the regulation of angiogenesis.

In addition to its role in blood

Protein Name: TMEM132E Divergent Transcript

The "TMEM132E-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM132E-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets